TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06213909

Intervention type: OTHER
Intervention: This is a retrospective analysis of health data from inpatient record, no intervention was designed
Description: This is a retrospective analysis of health data from inpatient record, no intervention was designed

Intervention type: OTHER
Intervention: This is a retrospective analysis of health data from inpatient record, no intervention was designed
Description: This is a retrospective analysis of health data from inpatient record, no intervention was designed

Intervention type: OTHER
Intervention: This is a retrospective analysis of health data from inpatient record, no intervention was designed
Description: This is a retrospective analysis of health data from inpatient record, no intervention was designed
Study: NCT04911946

Intervention type: OTHER
Intervention: Questionnaire
Description: After signing the informed consent form agreeing to participate in the study, the participants answered the questionnaire about diagnostic and therapeutic questions related to a clinical case of osteoporotic fracture in 4 scenarios: the initial care in the emergency room, at the time of discharge from hospital, during their outpatient return in 3 and 6 months.

Intervention type: OTHER
Intervention: Questionnaire
Description: After signing the informed consent form agreeing to participate in the study, the participants answered the questionnaire about diagnostic and therapeutic questions related to a clinical case of osteoporotic fracture in 4 scenarios: the initial care in the emergency room, at the time of discharge from hospital, during their outpatient return in 3 and 6 months.

Intervention type: OTHER
Intervention: Questionnaire
Description: After signing the informed consent form agreeing to participate in the study, the participants answered the questionnaire about diagnostic and therapeutic questions related to a clinical case of osteoporotic fracture in 4 scenarios: the initial care in the emergency room, at the time of discharge from hospital, during their outpatient return in 3 and 6 months.
Study: NCT05412680

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TOETVA
Description: TRANSORAL ENDOSCOPIC THYROIDECTOMY BY VESTIBULAR APPROACH

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional thyroidectomy
Description: conventional open thyroidectomy by cervical approach
Study: NCT05771298

Intervention type: DEVICE
Group type: OTHER
Intervention: 532nm KTP
Description: one to three treatment sessions

Intervention type: DEVICE
Group type: OTHER
Intervention: 585nm PDL
Description: one to three treatment sessions
Study: NCT06073392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video
Description: Educational video in animation mode

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video
Description: Educational video in animation mode

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video
Description: Educational video in animation mode

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational video
Description: Educational video in animation mode
Study: NCT04321395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vigabatrin
Description: Vigabatrin - Pill, 500 mg twice daily for 7 days (days 0-6), 1000 mg twice daily for 7 days (days 7-13), 1500 mg twice daily for 10 days (days 14-23), 1000 mg twice daily for 7 days (days 24-30), 500 mg twice daily for 7 days (days 31-37) and will discontinue treatment on day 38.
Study: NCT05623462

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The C-Mill virtual reality treadmill
Description: The C-Mill treadmill is an innovative device used for the training of impaired gait and balance. The C-Mill is an instrumented treadmill with interactive virtual reality games and applications.The instrument is supplied with a safety frame, body weight support, treadmill force plates, treadmill belt, adjustable handrails, cameras, user operating system, interactive visual screen and augmented reality projection.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy Program
Description: The Conventional Physical Therapy Program includes the following:~- Indoor open environment gait training exercises (over-ground gait training exercises.). (using obstacles, cones, stepper, balance board , and uneven surfaces) (either between or outside the parallel bar)
Study: NCT05325775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACER-801 50 mg BID
Description: 50 mg BID (twice daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACER-801 100 mg BID
Description: 100 mg BID (twice daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACER-801 200 mg BID
Description: 200 mg BID (twice daily)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06519591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab, LM-302, S-1, paclitaxel
Description: Cadonilimab 10mg/kg, LM-302 2.0mg/kg intravenous (IV) infusion on day 1, paclitaxel 20 mg/m2 intraperitoneal infusion on Days 1 and 8 plus oral S-1 80 mg/m2 for 14 consecutive days every 3 weeks.
Study: NCT06385015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored DPP Intervention
Description: The intervention includes 19 sessions (18 in-person and 1 on-demand) covering 24 DPP modules; each session is approximately an hour in length and will be moderated by a trained lifestyle coach. Lifestyle coaches are accessible, collaborative, and culturally competent diabetes care and education specialists trained and certified in the CDC's National DPP curriculum to provide effective guidance and support for program participants. Each group will meet regularly during the academic year, with six in-person sessions delivered per 10-week quarter (for each of three quarters) to allow for breaks during final exams and scheduled school recess (e.g., spring break). It will take place on UCLA campus.
Study: NCT06503445

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: education video
Description: the intervention group will watch the cardiac reahbiltation health education video.~the control group will watch the health educatopm video.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education video
Description: the intervention group will watch the cardiac reahbiltation health education video.~the control group will watch the health educatopm video.
Study: NCT05196763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the Supplemental Nutrition Assistance Program-Education
Description: The Supplemental Nutrition Assistance Program-Education is federal nutrition education provided in all U.S. states to the SNAP-eligible population.
Study: NCT05299385

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilition treatment(e.g leaflet) educated by hospital
Description: Active Comparator: subjects who are trained in accordance with the conventional manual treatment of Respiratory rehabilitation in the clinical institution and taking care home-based management.~The manual contents~* method of the conventional rehabilitation treatment~* intensity for aerobic exercise and anaerobic exercise

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital treatment based on Respiratory Rehabilitation Software
Description: Experimental: subjects who use the software as a home-based Digital Respiratory Rehabilitation software~It is intended for subjects who are prescribed a respiratory rehabilitation exercise to improve their physical condition. The software also helps them to do self-rehabilitation exercise.
Study: NCT04512287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Platelet Rich Plasma
Description: 2 sessions of Autologous PRP will be administered 15 days apart. Each injection will be 0.5 mL of PRP injected into the Peyronie's disease penile plaque.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Platelet Rich Plasma
Description: 2 sessions of Autologous PRP will be administered 15 days apart. Each injection will be 0.5 mL of PRP injected into the Peyronie's disease penile plaque.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Solution
Description: 2 sessions of saline injection will be administered 15 days apart. Each injection will be 0.5 mL of normal saline injected into the Peyronie's disease penile plaque.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Solution
Description: 2 sessions of saline injection will be administered 15 days apart. Each injection will be 0.5 mL of normal saline injected into the Peyronie's disease penile plaque.
Study: NCT05922033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patient-led Insulin (intervention group)
Description: Individuals randomized to this arm will initiate night-time insulin of 10 units. The type of basal insulin will be left to the discretion of the provider with levemir or glargine preferred over NPH. On day 0 of initiation of insulin, the patient will initiate night-time (or prior to sleep if alternate sleep schedule) insulin of 10 units (glargine, detemir, or NPH). Patient will check their fasting blood glucose in the morning and record their values. If the value is below 70 they will decrease their insulin dosage that night by 2 units; if the value is above 95 they will increase their insulin dosage that night by 2 units; and if the value is between 70 and 95, they will maintain the same insulin dosage that night. The patients will continue this algorithm for the remainder of the pregnancy. If the patient does not have a fasting blood glucose, the patient will maintain the dose of basal insulin at the prior dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Provider-led Insulin (standard care)
Description: Individuals randomized to this arm will receive standard care and titration of insulin will be determined by the individual providers.
Study: NCT05388916

Intervention type: OTHER
Intervention: Cosentyx
Description: Prospective observational cohort study. There is no treatment allocation. Patients administered Cosentyx by prescription will be enrolled.
Study: NCT06040320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin
Description: Given at 1.8 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin
Description: Given at 1.8 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin
Description: Given at 1.8 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin
Description: Given at 1.8 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given at 375 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given at 375 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given at 375 mg/m\^2
Study: NCT04820400

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immersive VR Video
Description: The VR-360 video will be custom-made for the burn patient population. Through a review of current evidence for video scenarios/patients surveys, the study team will define and implement the key components appropriate for acute procedural pain such as type, duration and severity in this patient population. Next, patients will be asked about preferred pain relief elements (e.g. individual colours, geographical locations, sounds, etc.) that would help to design a video scenario. Finally, using a Likert pain scale, patients will be asked to rate each individual descriptor that exacerbates or alleviates pain. For instance, the colour red may be associated with 'flames', 'heat' and 'burns', and thus elevated pain, the colour blue may have the opposite effect, representing 'cooling' or 'cold'.~Combined, this information will be used to create a VR-360 video geared towards alleviating acute procedural pain in patients with burn injuries undergoing dressing changes after skin graft.
Study: NCT06040320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given at 375 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHP
Description: Cyclophosphamide (750 mg/m\^2) + doxorubicin (50 mg/m\^2) + prednisone (100 mg days 2-6)
Study: NCT05442619

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Venous blood collection
Description: Venous blood will be drawn from newborns.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Venous blood collection
Description: Venous blood will be drawn from newborns.
Study: NCT06040320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHP
Description: Cyclophosphamide (750 mg/m\^2) + doxorubicin (50 mg/m\^2) + prednisone (100 mg days 2-6)
Study: NCT06023225

Intervention type: BEHAVIORAL
Intervention: Pain
Description: Postoperative pain levels

Intervention type: BEHAVIORAL
Intervention: Opioid use
Description: Postoperative opioid use
Study: NCT05651919

Intervention type: BIOLOGICAL
Intervention: Blood test
Description: During the routine blood test of the patient, 4 more tubes of 4 milliliters (mL) will be collected to make a biological collection of PBMC and plasma for further analysis.

Intervention type: BIOLOGICAL
Intervention: Blood test
Description: During the routine blood test of the patient, 4 more tubes of 4 milliliters (mL) will be collected to make a biological collection of PBMC and plasma for further analysis.
Study: NCT05837741

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard hypercaloric hyperproteic oral nutritional supplement
Description: Patients will receive nutritional support with Standard hypercaloric hyperproteic oral nutritional supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Leucine-enriched hypercaloric hyperproteic oral nutritional supplement
Description: Patients will receive nutritional support with Leucine-enriched hypercaloric hyperproteic oral nutritional supplement
Study: NCT05025826

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phycocare
Description: Phycocare every day during 9 months (except days of chemotherapy: no Phycocare)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo every day during 9 months (except days of chemotherapy = no Placebo)
Study: NCT05431296

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom ONE Continuous Glucose Monitoring System
Description: The Dexcom ONE is comprised of a sensor, transmitter and display device (receiver and/or compatible smart device). The system features a redesigned, one-touch auto-applicator and sleek, discreet transmitter. CGM involves insertion of a small plastic cannula to the subcutaneous tissue of the abdominal skin by members of the study team. The cannula is attached to a small data. The cannula is attached to a small transmitter which is taped to the skin and sends data about interstitial glucose via Bluetooth to a receiver which displays a blood glucose reading. The Dexcom G6 sends glucose readings to a compatible smart device or the Dexcom receiver every 5 minutes.
Study: NCT04849572

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Education
Description: * Week 1-2: All 100 participants will have sleep parameters recorded as baseline for the first two weeks.~* Week 3: 50 participants (Arm 1) will watch a 10 to 20 minute sleep hygiene video followed by a post-test questionnaire to confirm participation and understanding.~* Week 5: Arm 1 will again view the educational video at week 5~* Week 6-8: Baseline sleep data on all participants will be downloaded for review and the PSQI questionnaire administered for both groups. Participants will be also be asked if they underwent any major health crisis during the study period which may have impacted their sleep (hospitalization, significant medication changes which they believe impacted sleep, any use of illicit drugs during the study periods or significant increase in alcohol consumption (e.g., doubling).~* Week 9: Arm 1 will continue re-education~* Week 11: Arm 1 continues education~* Week 12-14: Data from Oura ring will be downloaded and PSQI administered to both groups.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Sleep Education
Description: * Week 1-2: All 100 participants will have sleep parameters recorded as baseline for the first two weeks.~* Week 3: 50 participants (Arm 2) will be controls with no education.~* Week 6-8: Baseline sleep data on all participants will be downloaded for review and the PSQI questionnaire administered for both groups. Participants will be also be asked if they underwent any major health crisis during the study period which may have impacted their sleep (hospitalization, significant medication changes which they believe impacted sleep, any use of illicit drugs during the study periods or significant increase in alcohol consumption (e.g., doubling).~* Week 9: Arm 2 will join in for video education along with post-test~* Week 11: Arm 2 will undergo reeducation with post-test for 20 mins~* Week 12-14: Data from Oura ring will be downloaded and PSQI administered to both groups.
Study: NCT04821583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone is orally administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is orally administered.
Study: NCT05649293

Intervention type: OTHER
Intervention: measure vitamin b6 in serum
Description: * Vitamin B6 levels can be determined by using Enzyme- linked Immuno-sorbent Assay Kit For vitamin B6 . or Chemiluminescence Immunoassays (CLIA) .~* Venous blood samples will be taken from each patient. Use a serum separator tube and allow samples to clot for 10-20 minutes at room temperature and then centrifuged for 20 minutes at speed of 2000-3000 rpm (round per minute).~* Remove supernatant, if precipitation appeared, Centrifuge again.~* Extract as soon as possible after Samples collection, and should be tested as soon as possible after the extraction.~* If not, samples must be stored in aliquot at -20°C (≤ 1 month) or -80°C (≤ 2 months) to avoid loss of bioactivity and contamination.~* Hemolyzed Sample will be avoided , as hemolysis will interfere with the results .

Intervention type: OTHER
Intervention: measure vitamin b6 in serum
Description: * Vitamin B6 levels can be determined by using Enzyme- linked Immuno-sorbent Assay Kit For vitamin B6 . or Chemiluminescence Immunoassays (CLIA) .~* Venous blood samples will be taken from each patient. Use a serum separator tube and allow samples to clot for 10-20 minutes at room temperature and then centrifuged for 20 minutes at speed of 2000-3000 rpm (round per minute).~* Remove supernatant, if precipitation appeared, Centrifuge again.~* Extract as soon as possible after Samples collection, and should be tested as soon as possible after the extraction.~* If not, samples must be stored in aliquot at -20°C (≤ 1 month) or -80°C (≤ 2 months) to avoid loss of bioactivity and contamination.~* Hemolyzed Sample will be avoided , as hemolysis will interfere with the results .
Study: NCT04069052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide
Description: Gaseous pulmonary vasodilator, SoKinox (nitric oxide) flowed into a mask and breathed in.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Room air (placebo) flowed into a mask and breathed in.
Study: NCT04906135

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Experimental manipulation of stimulation parameters
Description: This translational mechanistic study involves changing stimulation parameters (i.e., experimental manipulation) for measuring the electrically evoked compound action potential in order to understand the pathophysiology of the auditory system in patients with Usher syndrome.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental manipulation of stimulation parameters
Description: This translational mechanistic study involves changing stimulation parameters (i.e., experimental manipulation) for measuring the electrically evoked compound action potential in order to understand the pathophysiology of the auditory system in patients with Usher syndrome.
Study: NCT04732754

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aerobic exercise + Theobroma cocoa (AETC)
Description: Daily consumption of 500mg cocoa in capsules and 3 sessions of physical exercise / week, 50 min / session, with moderate intensity of 50-70% of VO2peak for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Group (CG)
Description: Daily consumption of placebo capsules for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise (AE)
Description: Daily consumption of placebo capsules and 3 sessions of physical exercise / week, 50 min / session, with moderate intensity of 50-70% of VO2peak for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Theobroma Cocoa (TC)
Description: Daily consumption of 500mg cocoa in capsules for 8 weeks.
Study: NCT05408520

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Targeted Muscle Reinnervation
Description: When a nerve is severed or injured, it attempts to regenerate. The TMR procedure will transfer the transected nerves to adjacent muscle nerves in efforts to encourage the nerve to regenerate in an organized fashion.
Study: NCT06421220

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative injection of indocyanine green
Description: Submucosal injection of indocyanine green into the gastric mucosa prior to surgery， indocyanine green，25mg，powder，once